StockData
Ocugen, Inc. logo

Ocugen, Inc. (OCGN) bonds

OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$0.76−0.02 (-2.11%)

Close on Nov 17, 2026Market cap $256.61MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$1.75M
$20.00K due within a year
Net debt
-$98.30M
After $100.05M of cash
Implied interest rate
18.06%
FY2025 interest ÷ average debt
Interest coverage
-12.1×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Ocugen's 10-Q for the period ended Jun 30, 2026

IssueCouponMaturesAmount issuedCarrying value
6.75% Convertible Senior Notes Due 2034
Convertible at $3 a share
6.75%2034$130.00M–
6.75% Convertible Senior Notes Due 2034, Over-Allotment Option
Convertible
–2034$15.00M–
Debt Financing Transaction12.25%––$0

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawn
EB-5 Loan Agreement$20.00M$1.50M

See a number that looks wrong?